- Home
- PROV vs STTK Comparison
PROV vs STTK Comparison
Compare PROV & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PROV
- STTK
- Stock Information
- Founded
- PROV 1956
- STTK 2016
- Country
- PROV United States
- STTK United States
- Employees
- PROV N/A
- STTK N/A
- Industry
- PROV Savings Institutions
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- PROV Finance
- STTK Health Care
- Exchange
- PROV Nasdaq
- STTK Nasdaq
- Market Cap
- PROV 102.0M
- STTK 83.8M
- IPO Year
- PROV 1996
- STTK 2020
- Fundamental
- Price
- PROV $15.59
- STTK $1.92
- Analyst Decision
- PROV Hold
- STTK Hold
- Analyst Count
- PROV 1
- STTK 6
- Target Price
- PROV $16.50
- STTK $2.67
- AVG Volume (30 Days)
- PROV 6.2K
- STTK 1.6M
- Earning Date
- PROV 10-27-2025
- STTK 08-14-2025
- Dividend Yield
- PROV 3.56%
- STTK N/A
- EPS Growth
- PROV N/A
- STTK N/A
- EPS
- PROV 0.93
- STTK N/A
- Revenue
- PROV $39,666,000.00
- STTK $2,997,000.00
- Revenue This Year
- PROV $7.74
- STTK N/A
- Revenue Next Year
- PROV $4.06
- STTK N/A
- P/E Ratio
- PROV $16.94
- STTK N/A
- Revenue Growth
- PROV 1.90
- STTK N/A
- 52 Week Low
- PROV $12.98
- STTK $0.69
- 52 Week High
- PROV $16.70
- STTK $3.95
- Technical
- Relative Strength Index (RSI)
- PROV 57.02
- STTK 72.13
- Support Level
- PROV $15.35
- STTK $1.68
- Resistance Level
- PROV $15.79
- STTK $2.04
- Average True Range (ATR)
- PROV 0.20
- STTK 0.19
- MACD
- PROV 0.02
- STTK 0.09
- Stochastic Oscillator
- PROV 68.75
- STTK 89.29
About PROV Provident Financial Holdings Inc.
Provident Financial Holdings Inc is a holding company of Provident Savings Bank, F.S.B. Through the bank, it is engaged in providing community and mortgage banking services to consumers and small to mid-sized businesses in the Inland Empire region of Southern California. The company's business segment is Bank. The Bank's activities include attracting deposits, offering banking services, and originating and purchasing single-family, multi-family, commercial real estate, construction, and other mortgage loans and, to a lesser extent, commercial business and consumer loans held for investment.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.